Mumbai-based Elder Pharmaceuticals has announced the introduction of a line of over-the-counter "inhalers for nasal congestion." The intranasal products will be sold under the Solo brand, a range of products that also includes a pain balm, cough drops, and throat lozenges. The company said that it will target rural markets with the Solo brand. Elder Pharmaceuticals … [Read more...] about Elder Pharma introduces intranasal products
News
Dance Biopharm completes $9.5 million financing
Dance Biopharm has announced the completion of a $9.5 million private placement that will fund clinical trials of its Dance 501 inhaled insulin. The Phase 2 program for Dance 501 is complete, according to the company's web site, and Phase 3 trials are being planned. Earlier this month, Dance announced that it had hired Tyler Martin in the newly created position of … [Read more...] about Dance Biopharm completes $9.5 million financing
Lupin begins selling valved holding chamber licensed from InspiRX in the US
Lupin Pharmaceuticals has announced the launch of the InspiraChamber valved holding chamber after it acquired exclusive US rights to the device from InspiRX. The InspiraChamber is being sold as part of a package with pediatric face masks, including the SootherMask, which has a slot for a pacifier. InspiRX CEO Michael Amato commented, "The agreement enables the … [Read more...] about Lupin begins selling valved holding chamber licensed from InspiRX in the US
AstraZeneca gets temporary injunction to stop Actavis sales of generic version of Pulmicort Respules
The United States Court of Appeals for the Federal Circuit has granted AstraZeneca's request for a temporary injunction stopping Actavis from further sales of its budesonide inhalation suspension, according to Actavis. AstraZeneca has appealed the decision earlier this month that ruled US Patent No. 7,524,834 was invalid, after which Actavis announced the launch of … [Read more...] about AstraZeneca gets temporary injunction to stop Actavis sales of generic version of Pulmicort Respules
Adapt Pharma gets Fast Track designation for intranasal naloxone
The FDA has granted Adapt Pharma Fast Track designation for its intranasal naloxone for the treatment of opioid overdose, the company said. Adapt Pharma licensed the product from Lightlake Therapeutics in December 2014. In the same month, Lightlake began a new trial of the drug for the opiod overdose reversal indication. Funding for the trial has been provided by the … [Read more...] about Adapt Pharma gets Fast Track designation for intranasal naloxone
Celon Pharma and Lupin team up to develop fluticasone/salmeterol DPI
Lupin Limited and Polish biopharmaceutical company Celon Pharma have announced that they will co-develop a generic version of GSK's Advair Diskus. Celon, which currently markets a fluticasone/salmeterol DPI called Salmex in Poland, will supply the the product to Lupin, and Lupin will commercialize the product in North America and "other key markets." Lupin CEO … [Read more...] about Celon Pharma and Lupin team up to develop fluticasone/salmeterol DPI
Actavis launches generic version of Pulmicort Respules
Actavis has announced that after the United States District Court for the District of New Jersey denied AstraZeneca's request for a permanent injunction and ruled that US Patent No. 7,524,834 is invalid, Actavis launched its generic version of AstraZeneca's Pulmicort Respules budesonide inhalation suspension in 0.25 and 0.5 mg vials. The FDA approved Actavis's ANDA … [Read more...] about Actavis launches generic version of Pulmicort Respules
Flonase now available over the counter in the US
GSK has relied heavily on social media to get out the word that its Flonase fluticasone propionate nasal spray is now available over the counter in the United States. The FDA approved Flonase OTC in July 2014. On February 4, 2015, Flonase Twitter and Facebook accounts announced the availability of the … [Read more...] about Flonase now available over the counter in the US
PARI paying for nebulizer compressors for patients using Kitabis Pak
PARI has announced that it has begun supplying nebulizer compressors to patients using its new Kitabis Pak through a program called PARI Provide. Kitabis Pak, which includes generic tobramycin inhalation solution packaged with a PARI LC PLUS nebulizer, was approved by the FDA for the treatment P. aeruginosa infections in cystic fibrosis patients in December 2014. The … [Read more...] about PARI paying for nebulizer compressors for patients using Kitabis Pak
Tyler Martin joins Dance Biopharm as President
Dance Biopharm has announced the appointment of former Dynavax chief medical officer and president J. Tyler Martin as President, a newly created position. Martin has also been appointed a member of the board of directors. From 2003-2006, Martin was a vice president of Chiron, where he worked on the development of Tobi tobramycin inhalation powder. Dance Chairman … [Read more...] about Tyler Martin joins Dance Biopharm as President